VKTX Collapses After Phase 2 Results Shake Investor Confidence
Oral obesity breakthrough overshadowed by tolerability concerns as VK2735 trial sends shockwaves through biotech.
Viking Therapeutics (NASDAQ: VKTX), a rising star in the biotech sector, saw its stock collapse nearly 40% after unveiling Phase 2 results for its oral weight-loss drug, VK2735. The sell-off left investors stunned, despite promising efficacy data that had initially positioned the company as a potential rival in the booming GLP-1 obesity drug market.
The trial delivered results that on paper look like a breakthrough. VK2735 achieved up to 12.2% weight loss in just 13 weeks, a figure that surpasses many early-stage obesity treatments. Even more impressive, 97% of patients lost at least 5% of their body weight, while nearly 80% shed more than 10%—compared to only 1.3% weight loss in the placebo group. Those numbers made headlines as a strong case for an effective oral alternative in a space dominated by injectable therapies.
But alongside the excitement came a serious caveat. The 28% discontinuation rate, compared to 18% for placebo, shook confidence in the drug’s commercial viability. The primary reason: tolerability issues. Patients reported gastrointestinal side effects, with 58% experiencing nausea and 26% reporting vomiting. While most side effects were classified as mild to moderate, the sheer rate of dropouts raised concerns about whether patients in the real world would stay on the medication long enough to benefit.
The market reaction was brutal. Shares of VKTX tumbled as much as 45% intraday, underscoring just how fragile sentiment can be when biotech innovation collides with safety concerns. For a company that had gained momentum as a possible challenger to giants like Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO)—both leaders in the GLP-1 obesity treatment space—the sell-off marked a harsh reality check.
Investors and analysts are now divided. Bulls argue that the efficacy data is too strong to ignore, suggesting the sell-off is an overreaction and a potential buying opportunity. They believe that with dose optimization or alternative formulations, Viking could overcome the tolerability hurdle. On the other hand, bears point to the crowded obesity drug pipeline, highlighting that Lilly and Novo Nordisk already have oral candidates with better safety profiles, making it hard for VKTX to secure a foothold without major adjustments.
Speculation is also growing about a buyout scenario. Some believe that if Viking can refine its trial design or pivot to injectable versions, big pharma could swoop in with an acquisition offer. This buzz has fueled intense discussion across trading platforms, with retail and institutional investors debating whether the 40% crash represents capitulation or simply the first leg of a longer decline.
For now, Viking Therapeutics (VKTX) finds itself at a crossroads. The company has proven that oral weight-loss drugs can deliver competitive results, but patient tolerability remains the elephant in the room. Whether this is a temporary setback or a structural limitation will determine not just the future of VK2735, but also Viking’s place in one of the most lucrative and competitive segments of modern biotech.